Point72 Asset Management L.P. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM)

Point72 Asset Management L.P. lifted its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 46.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 688,790 shares of the company's stock after purchasing an additional 218,143 shares during the quarter. Point72 Asset Management L.P. owned 0.86% of Immunome worth $7,315,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IMNM. Enavate Sciences GP LLC bought a new stake in shares of Immunome during the 4th quarter valued at $36,939,000. JPMorgan Chase & Co. raised its stake in shares of Immunome by 2,540.4% during the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock valued at $6,888,000 after purchasing an additional 624,045 shares during the period. Granahan Investment Management LLC bought a new stake in shares of Immunome during the 4th quarter valued at $3,337,000. Renaissance Technologies LLC raised its stake in shares of Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock valued at $3,356,000 after purchasing an additional 304,700 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Immunome by 127.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company's stock worth $5,310,000 after purchasing an additional 280,000 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Immunome

In related news, Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares of the company's stock, valued at $193,879.15. This trade represents a 42.13% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall acquired 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $7.29 per share, with a total value of $999,459.00. Following the transaction, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at approximately $5,881,105.44. The trade was a 20.47% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 156,400 shares of company stock worth $1,160,495. 8.60% of the stock is currently owned by insiders.

Immunome Stock Up 0.4%

Shares of Immunome stock traded up $0.03 during trading on Friday, hitting $8.49. 527,133 shares of the stock traded hands, compared to its average volume of 915,906. The stock has a market cap of $738.73 million, a price-to-earnings ratio of -1.05 and a beta of 2.00. The firm's fifty day moving average is $7.59 and its 200-day moving average is $9.64. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. On average, analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IMNM. Wedbush reaffirmed an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 target price on the stock. Guggenheim lowered their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, Lake Street Capital assumed coverage on Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $23.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.